转自：一度医药 然而，话锋一转，Onsi解释道："由于当前的市场环境，我们决定终止DeFianCe临床试验并进一步削减 内部开支。"这一决定，实则是Leap对sirexatamab研发路径的又一次"断舍离"。 回溯过往，sirexatamab的研发之路可谓一路"缩水"。今年1月，Leap基于Ⅱ期试验的初步数据，决定终 止sirexatamab与百济神州抗PD-1抗体替雷利珠单抗联合用于胃癌治疗的开发。此前，该试验另一组评估 sirexatamab作为CRC一线治疗的结果未达预期，促使公司将研发重心转向二线治疗。 而就在上个月，Leap还宣布将sirexatamab与默沙东Keytruda联合用于子宫内膜癌的开发"降优先级"。 2025年6月23日，生物科技领域传来一则令人唏嘘的消息：Leap Therapeutics（以下简称"Leap"）宣布扩 大裁员规模，此次将裁撤75%的员工，同时终止其唯一正在进行的临床试验。这一系列激进的"收缩"举 措，折射出生物科技行业在当下市场环境中面临的生存压力。 从裁员50%到75%：资金告急下的无奈升级 这家总部位于马萨诸塞州的生物科技公司，在短短一个月内经历了战略方向的重 ...

Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder valueCAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study ( ...

又是医药股爆发的一天！ 今日早盘，创新药率先爆发。三生国健涨超15%，刷新历史高点，舒泰神、科兴制药、百奥泰、君实生 物、键凯科技、贝达药业等涨幅靠前。港股市场创新药表现更猛，君实生物大涨超16%，乐普生物、加科 思、绿叶制药等上涨超7%，创新药板块涨幅超4%。中药板块亦迎来反弹，陇神戎发、华森制药、寿仙谷 等表现强劲。 分析人士认为，医药崛起有两大利好驱动。一是5月30日—6月3日，2025年美国临床肿瘤学会 （ASCO）年会将在美国芝加哥举行。2025年ASCO年会上，中国药企以70余项研究成果入选，国产创 新药再次闪耀世界舞台；二是5月27日消息，《上海市嘉定区进一步加快中医药传承创新发展三年行动计 划（2025—2027年）（草案）》公开征求意见。 大爆发 创新药再度大爆发。这次是君实生物打头阵，今早，该股一度涨超16%，港股创新药板块逆市大涨近 4%。 据长江证券点评，基于临床潜力，全球范围内多家药企已前瞻性布局DKK1靶点，其中君实生物的 JS015、安济盛的AGA2118、礼来制药的Sirexatamab的研发进度在全球范围内处于领先位置，均已进 入临床Ⅱ期阶段，辉瑞的RN564紧随其后，已进入 ...

FL-501 fully restored body composition and reversed key indicators of cachexia in preclinical modelsFindings confirm GDF-15's role in cachexia and support advancing FL-501 into the clinicCAMBRIDGE, Mass., April 25, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster presentation at the American Association for Cancer Research (AACR) Annual Me ...

Core Insights - Leap Therapeutics has presented updated data from the DeFianCe study, indicating that sirexatamab in combination with bevacizumab and chemotherapy shows statistically significant improvements in overall response rate (ORR) and progression-free survival (PFS) for colorectal cancer (CRC) patients with high DKK1 levels and those who have not received prior anti-VEGF therapy [1][2][3] Study Results - In patients with high DKK1 levels (n=44), the sirexatamab Experimental Arm demonstrated a 32% higher ORR (48.0% vs. 15.8%) and a median PFS of 9.36 months compared to 5.88 months in the Control Arm [3][4] - For patients without prior anti-VEGF therapy (n=95), the sirexatamab Experimental Arm showed a 22% higher ORR (55.1% vs. 32.6%) and a median PFS of 10.94 months compared to 8.34 months in the Control Arm [4][3] - Across the intent-to-treat population (n=188), the sirexatamab Experimental Arm had an ORR of 36.2% compared to 25.5% in the Control Arm, with median PFS still maturing [4][3] Market Opportunity - The combination therapy has a significant market opportunity, targeting approximately 30,000 second-line treated CRC patients in the US and 160,000 in the next seven largest markets, particularly among the 25-50% of patients with high DKK1 levels and the 50% who have not received prior anti-VEGF therapy [7] - There is potential to expand into first-line CRC treatment, with an estimated 45,000 patients in the US and 265,000 in the next seven largest markets [7] Future Plans - Leap Therapeutics is considering a registrational Phase 3 clinical trial to further evaluate the efficacy of sirexatamab in the identified patient populations [7][2] - The company has engaged a leading financial advisor to explore business development opportunities to advance the development of sirexatamab [7]